Last Updated: November 17, 2026

BRINEURA Drug Profile

« Back to Dashboard


Summary for Tradename: BRINEURA
High Confidence Patents:2
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for BRINEURA
Recent Clinical Trials for BRINEURA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
David L Rogers, MDPhase 1/Phase 2

See all BRINEURA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BRINEURA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BRINEURA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Biomarin Pharmaceutical Inc. BRINEURA cerliponase alfa Injection 761052 ⤷  Start Trial 2026-08-22 DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc. BRINEURA cerliponase alfa Injection 761052 ⤷  Start Trial 2030-09-13 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for BRINEURA Derived from Patent Text Search

No patents found based on company disclosures

Brineura Market Dynamics and Financial Trajectory: Cerliponase Alfa Revenue, Exclusivity, Competition, and Generic Risk

Last updated: November 1, 2026

Brineura, BioMarin Pharmaceutical’s cerliponase alfa, is the only FDA-approved disease-specific treatment for late-infantile neuronal ceroid lipofuscinosis type 2, or CLN2 disease. Its market is small but commercially durable because CLN2 is ultra-rare, treatment is lifelong, and therapy requires specialized intracerebroventricular administration every two weeks.

BioMarin’s Brineura revenue has increased from roughly $100 million annually in the early commercial period to more than $150 million in recent years. Growth is driven by diagnosis expansion, international access, and treatment of additional eligible patients rather than broad population penetration. The main long-term risks are the narrow patient pool, treatment-center capacity, reimbursement friction, manufacturing complexity, and the eventual emergence of competing enzyme-replacement or gene therapies.

What is Brineura and which patients does it treat?

Brineura is an enzyme replacement therapy containing cerliponase alfa, a recombinant human tripeptidyl peptidase 1, or TPP1. TPP1 deficiency causes CLN2 disease, a lysosomal storage disorder that leads to progressive neurodegeneration, seizures, motor decline, language loss, and premature death.

The FDA approved Brineura on April 27, 2017, for slowing the progression of ambulation impairment in symptomatic pediatric patients aged 3 years and older with late-infantile CLN2 disease. The European Commission approved the product in June 2017 under the brand name Brineura for the treatment of patients with a confirmed diagnosis of CLN2 disease. [1,2]

Product attribute Brineura detail
Active ingredient Cerliponase alfa
Biological target Tripeptidyl peptidase 1, or TPP1
Disease CLN2 disease, a subtype of neuronal ceroid lipofuscinosis
FDA approval April 27, 2017
Initial FDA population Symptomatic pediatric patients aged 3 years and older
Administration Intraventricular infusion through an implanted device
Dosing schedule 300 mg every other week
Commercial company BioMarin Pharmaceutical
Regulatory designation Orphan drug and breakthrough therapy development pathway
Primary efficacy measure Slower decline in motor function
Main commercial constraint Ultra-rare population and specialized administration

Treatment requires an implanted intraventricular access device and infusion over several hours. Patients also receive premedication and must be treated in qualified medical centers. These requirements create operational barriers to rapid market expansion but make substitution by conventional oral or subcutaneous products difficult.

How large is the CLN2 and Brineura market?

The addressable CLN2 population is small. Published epidemiology estimates vary by geography and ascertainment method, but CLN2 disease is generally estimated to occur in approximately one in 200,000 to one in 1 million live births. Diagnostic delays remain common because early symptoms can resemble epilepsy, developmental delay, or other neurodegenerative conditions.

The commercial market is larger than the annual number of newly diagnosed patients because treatment continues for years. Patients diagnosed in early childhood can remain on therapy through adolescence and, in some cases, adulthood. Revenue therefore reflects the cumulative treated population rather than annual incidence alone.

Market expansion drivers

BioMarin can expand Brineura revenue through four principal mechanisms:

  1. Earlier diagnosis through genetic testing and specialist awareness.
  2. Increased treatment penetration in Europe, the United States, and other reimbursed markets.
  3. Continued treatment of existing patients as the prevalent population grows.
  4. Extension of treatment into older patients and less clearly defined disease stages where physicians consider the benefit-risk profile acceptable.

The most attractive growth opportunity is diagnosis. The company has described CLN2 as substantially underdiagnosed, which leaves room for market expansion without a change in price or dose.

Commercial limitations

Brineura’s market remains structurally limited by:

  • Low disease prevalence.
  • High clinical and logistical requirements.
  • Dependence on specialized pediatric neurology centers.
  • Reimbursement negotiations for ultra-orphan therapy.
  • Potential discontinuation when neurodegeneration becomes advanced.
  • Competition from investigational gene therapies and next-generation lysosomal treatments.

The market is therefore a high-price, low-volume specialty franchise rather than a product with conventional pharmaceutical scale.

What is Brineura’s financial trajectory?

BioMarin reports Brineura as part of its product revenue portfolio. Public company filings indicate a steady increase in annual revenue after launch.

Fiscal year Approximate Brineura net product revenue Commercial interpretation
2018 About $50 million First full commercial ramp
2019 About $80 million Expansion of treatment centers and diagnosis
2020 About $100 million Continued patient accumulation despite pandemic disruption
2021 About $120 million International and prevalent-patient growth
2022 About $135 million Ongoing treated-patient expansion
2023 About $150 million Mature ultra-orphan growth profile
2024 More than $160 million Continued contribution from treatment persistence and new diagnoses

BioMarin’s annual reports are the controlling source for reported revenue, and individual year figures may differ slightly depending on the company’s presentation of product sales, foreign exchange, and reporting-period adjustments. [3-7]

What explains Brineura revenue growth?

Brineura revenue growth has not depended on large-scale market access. The main drivers are:

  • Increased recognition of CLN2 disease.
  • More genetic and enzyme-based diagnostic testing.
  • Expansion of reimbursement coverage.
  • Longer treatment duration among surviving patients.
  • Broader use across eligible pediatric age groups.
  • Higher penetration outside the initial U.S. launch market.

The product’s revenue base has become more predictable as the prevalent treated population increases. New-patient starts add revenue gradually, while discontinuations and mortality offset part of the growth.

Revenue quality and margin characteristics

Brineura has characteristics associated with attractive rare-disease economics:

  • High annual treatment value per patient.
  • Limited direct competition.
  • Specialty distribution.
  • Disease-specific clinical expertise.
  • Manufacturing complexity that discourages rapid replication.

Its revenue quality is constrained by the small number of patients and the concentration of sales in specialized centers. A single reimbursement decision, treatment-center closure, manufacturing interruption, or safety signal can affect a meaningful portion of the franchise.

BioMarin does not generally disclose Brineura-specific operating profit. Product-level profitability is likely supported by orphan-drug pricing and a biologic manufacturing platform, but the product also carries substantial costs for clinical support, patient services, pharmacovigilance, logistics, and specialized administration.

When does Brineura lose regulatory exclusivity?

Brineura received seven years of U.S. orphan-drug exclusivity beginning with its FDA approval on April 27, 2017. That exclusivity period generally ran through April 2024, subject to the statutory framework and the timing of any subsequent eligible designation or regulatory action.

Orphan-drug exclusivity prevents FDA approval of the same drug for the same orphan indication during the exclusivity period, subject to exceptions such as clinical superiority. It does not prevent all competing products, and it does not replace patent protection.

Brineura also received pediatric regulatory benefits. FDA materials identify the product as having been developed for a serious rare pediatric disease, and BioMarin received a rare pediatric disease priority review voucher after approval. [1,8]

Likely post-exclusivity market position

Loss of orphan exclusivity does not create an immediate conventional generic launch risk. Brineura is a complex biologic administered through an implanted intraventricular device. A competitor would need to establish:

  • A comparable biological product or another lawful approval pathway.
  • Adequate clinical comparability or clinical efficacy.
  • Manufacturing consistency.
  • Device and infusion compatibility.
  • A qualified distribution and treatment network.
  • Reimbursement acceptance.

The practical competitive risk is therefore more likely to come from an alternative therapy than from a simple interchangeable generic.

What patents protect Brineura?

Brineura’s protection is based on a combination of biologic patents, manufacturing know-how, formulation and stability controls, delivery procedures, regulatory exclusivity, and clinical infrastructure. The product’s most important commercial barriers are not limited to a single composition-of-matter patent.

Relevant protection categories include:

Protection category Commercial relevance
Recombinant TPP1 composition Protects the biologic molecule or defined molecular forms
Cell line and expression technology Limits practical replication of the manufacturing process
Purification and formulation Protects product quality, stability, and usable concentration
Intraventricular administration Supports the product-specific treatment method
Device and infusion compatibility Creates operational barriers for competing products
Clinical and regulatory data Delays or complicates approval of alternatives
Trade secrets Protects process parameters not fully disclosed in patents
Orphan exclusivity Restricted approval of the same drug for the same indication

Brineura is a biologic and does not have the same Orange Book patent-listing framework used for conventional small-molecule drugs. Biologic patent and exclusivity information is evaluated through FDA biologics records, the Purple Book, patent databases, FDA approval documents, and litigation records rather than through a standard Orange Book listing.

What is the Orange Book status of Brineura?

Brineura is not a conventional small-molecule drug and should not be analyzed as an ordinary Orange Book product. Its regulatory reference is the FDA biologics framework and the Purple Book. The absence of a conventional Orange Book listing does not mean the product lacks patent protection.

How strong is the Brineura patent estate?

The estate is commercially strong against near-term copying because Brineura combines:

  • A difficult-to-reproduce recombinant enzyme.
  • Specialized manufacturing controls.
  • Intraventricular delivery.
  • Orphan-disease clinical data.
  • A concentrated treatment-center network.
  • Limited natural-history data for CLN2 disease.

The estate is less insulated against a clinically differentiated competitor. A gene therapy or other disease-modifying treatment could avoid direct reliance on cerliponase alfa patents and compete on convenience, durability, or total treatment burden.

Are there Paragraph IV challenges to Brineura?

There is no widely reported major Paragraph IV litigation campaign against Brineura comparable to challenges involving high-volume small-molecule products. Paragraph IV litigation is primarily associated with abbreviated new drug applications and Orange Book-listed patents. Brineura’s biologic status makes a conventional ANDA-based Paragraph IV pathway inapplicable.

A future competitor could pursue a biosimilar or interchangeable-biologic strategy under the Public Health Service Act. That pathway would involve FDA biosimilar requirements, including analytical, biological, and potentially clinical evidence. The competitor would also need to address patent disputes under the biologics patent-resolution framework.

Which companies are challenging Brineura?

No approved product currently has an equivalent commercial position to Brineura for CLN2 disease. Competitive pressure is concentrated in clinical development rather than marketed products.

Potential challengers include:

  • Gene-therapy developers seeking one-time or durable correction of TPP1 deficiency.
  • Academic groups developing viral-vector approaches.
  • Companies developing alternative enzyme-replacement strategies.
  • Sponsors pursuing treatments for broader neuronal ceroid lipofuscinosis populations.
  • Manufacturers with biologics infrastructure capable of developing a cerliponase alfa biosimilar.

A direct biosimilar would face a smaller market than a conventional biologic but could still be commercially viable because of high annual treatment value and limited switching requirements if the product receives favorable reimbursement.

What patent litigation and settlement risks affect Brineura?

No major publicly disclosed patent settlement has defined the Brineura market in the manner seen with blockbuster small-molecule medicines. The principal legal risks are more likely to arise from:

  • Patent disputes involving recombinant TPP1 production.
  • Claims covering purification or formulation.
  • Device-related intellectual property.
  • Trade-secret disputes involving manufacturing processes.
  • Patent challenges by a biosimilar developer.
  • Litigation over a competing gene-therapy platform.

A settlement with a biosimilar company would be unlikely to have the same financial effect as a settlement for a high-volume medicine. The market’s value is concentrated, but the number of potential entrants is small.

What is the FDA regulatory status of Brineura?

Brineura remains FDA-approved for symptomatic pediatric patients aged 3 years and older with late-infantile CLN2 disease. The FDA approval was based on evidence that treatment slowed decline in motor function, assessed using a CLN2-specific rating scale. The approval was granted under an accelerated pathway, with confirmatory obligations relating to clinical benefit. [1]

The product’s regulatory profile creates both protection and risk:

  • The serious and rapidly progressive nature of CLN2 supports expedited review.
  • Limited patient numbers constrain trial size.
  • Natural-history comparisons are important because randomized trials are difficult.
  • Expanded use in older patients may require additional evidence.
  • Safety monitoring is critical because administration requires an implanted device.

How does Brineura compare with competing rare-disease drugs?

Attribute Brineura Conventional enzyme replacement Gene therapy
Administration Intraventricular Usually intravenous or subcutaneous Often one-time or limited dosing
Treatment frequency Every two weeks Often weekly or biweekly Potentially one-time
Patient population CLN2 disease Disease-specific May target broader or narrower genetic groups
Commercial model Lifelong specialty treatment Chronic treatment High upfront value
Key barrier Device and treatment-center dependence Infusion burden and chronic cost Durability, safety, and manufacturing
Main competitive risk Alternative CLN2 therapy Limited direct overlap Durable disease modification

Brineura’s principal advantage is established clinical use and regulatory approval. Its principal disadvantage is treatment burden. A durable gene therapy could exert pressure even if it does not become directly interchangeable.

What generic entry risks exist for Brineura?

Near-term generic risk

Near-term conventional generic risk is low. Brineura is a biologic, requires specialized administration, and serves a very small patient population.

Biosimilar risk

Biosimilar risk is moderate over the long term but limited by economics and technical complexity. A developer would need to justify the cost of an analytical and clinical program for a small global market. The product’s high per-patient revenue could offset the small volume, but manufacturing and commercial infrastructure would remain difficult.

Gene-therapy risk

Gene-therapy risk is strategically more important than generic risk. A successful gene therapy could reduce the need for lifelong intraventricular dosing and shift the market from recurring revenue to a one-time treatment model. It would also compete through clinical differentiation rather than patent expiration.

What are the geographic markets for Brineura?

BioMarin markets Brineura in the United States and international regions where regulators have approved treatment and reimbursement has been obtained. Europe is strategically important because multiple countries have centralized or specialist reimbursement systems for ultra-rare diseases.

Geographic revenue growth depends on:

  • National reimbursement decisions.
  • Availability of pediatric neurology centers.
  • Genetic testing access.
  • Local treatment guidelines.
  • Import and cold-chain requirements.
  • Ability to implant and maintain the delivery device.

The United States typically supports higher treatment economics, while European revenue depends more heavily on country-specific health technology assessment and negotiated reimbursement.

What manufacturing and intellectual-property barriers protect Brineura?

Brineura manufacturing is difficult to replicate because the product requires recombinant protein expression, purification, characterization, sterile production, release testing, and long-term stability control. Small variations in glycosylation, aggregation, potency, or impurity profile can affect regulatory comparability.

The intraventricular route creates a second barrier. A competing product must be safe and effective when delivered into the cerebrospinal-fluid environment, not merely demonstrate systemic exposure. Device compatibility, infection control, infusion duration, and patient monitoring all affect the commercial value of a substitute.

These barriers support continued revenue after orphan exclusivity ends, although they do not eliminate competition from a product with a different mechanism or delivery method.

What is the Brineura investment outlook?

Brineura is a durable but limited-scale asset. Its financial profile has four defining characteristics:

  1. Revenue is recurring because patients require chronic treatment.
  2. Growth is linked to diagnosis and patient accumulation.
  3. Competition is constrained by technical and logistical barriers.
  4. Long-term upside is capped by the size of the CLN2 population.

The product can continue to generate material cash flow for BioMarin, but it is unlikely to become a major company-wide growth engine. Its strategic value is higher than its absolute revenue because it supports BioMarin’s rare-disease platform, specialist relationships, manufacturing capabilities, and regulatory expertise.

The primary downside scenario is not a rapid generic collapse. It is gradual displacement by a durable gene therapy, slower diagnosis growth, reimbursement pressure, or treatment discontinuation as patients progress.

Key Takeaways

  • Brineura is BioMarin’s cerliponase alfa therapy for CLN2 disease.
  • FDA approval occurred in April 2017, and European approval followed in 2017.
  • Annual revenue has increased from roughly $50 million during the initial launch period to more than $160 million in recent years.
  • Revenue is supported by chronic treatment, patient accumulation, diagnosis expansion, and ultra-orphan pricing.
  • U.S. orphan-drug exclusivity generally ended in April 2024.
  • Conventional Paragraph IV risk is low because Brineura is a biologic rather than an Orange Book small-molecule product.
  • Biosimilar risk is limited by manufacturing complexity, specialized administration, and the small patient pool.
  • Gene therapy is the most significant long-term competitive threat.
  • Brineura’s patent and commercial protection extends beyond molecule claims to manufacturing, formulation, delivery, device compatibility, regulatory data, and trade secrets.
  • The product is likely to remain a durable niche franchise, but its growth ceiling is constrained by CLN2 prevalence.

FAQs About Brineura Market Dynamics and Exclusivity

What is the annual cost of Brineura treatment?

The annual cost depends on the patient’s weight, dosing requirements, payer discounts, treatment setting, and country. U.S. list-price economics for rare biologics can produce a high six-figure annual treatment value, while net prices vary by reimbursement contract.

Is Brineura a gene therapy?

No. Brineura is an enzyme replacement therapy that supplies recombinant cerliponase alfa, the deficient TPP1 enzyme. It requires repeated intraventricular administration.

Can adults receive Brineura?

Brineura was initially approved for pediatric patients aged 3 years and older. Continued use in older patients can depend on disease status, clinical judgment, local labeling, and reimbursement policy.

What is the main clinical weakness of Brineura?

The main weakness is treatment burden. Patients require lifelong, repeated intraventricular infusions through an implanted access device, creating infection, device, monitoring, and treatment-center risks.

Could a Brineura biosimilar receive interchangeability?

A biosimilar developer could seek an interchangeable designation if it satisfies applicable FDA requirements. Interchangeability would depend on the totality of evidence, switching data, product labeling, and device-administration considerations.

References

  1. U.S. Food and Drug Administration. (2017). Brineura (cerliponase alfa) prescribing information.
  2. European Medicines Agency. (2017). Brineura: EPAR product information.
  3. BioMarin Pharmaceutical Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  4. BioMarin Pharmaceutical Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  5. BioMarin Pharmaceutical Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  6. BioMarin Pharmaceutical Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  7. BioMarin Pharmaceutical Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
  8. U.S. Food and Drug Administration. (2024). Rare pediatric disease priority review voucher program.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.